The lenalidomide derivative loaded and quercetin modified MIL-100 based novel drug delivery system for breast cancer treatment

Yükleniyor...
Küçük Resim

Tarih

2025

Dergi Başlığı

Dergi ISSN

Cilt Başlığı

Yayıncı

Editions de Sante

Erişim Hakkı

info:eu-repo/semantics/closedAccess

Araştırma projeleri

Organizasyon Birimleri

Dergi sayısı

Özet

Lenalidomide (L0) is an immunomodulatory agent with a range of effects, including anticancer and anti-inflammatory activity, and is commonly utilized in treating multiple myeloma. A derivative of lenalidomide (L1) has been synthesized to enhance its effects and to target different cancer cell types. In this study, the lenalidomide derivative L1, with the chemical structure 1-[2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl]-3-(p-tolyl)urea, was loaded onto a novel drug delivery system (DDS), and its activity was assessed towards triple-negative breast cancer cell lines (TNBC). MIL-100, a subclass of metal-organic framework (MOF) structures, was synthesized via a microwave-assisted hydrothermal method. MIL-100 was modified with quercetin (QC) as a linker, and its drug loading capacity was optimized, achieving a 95.18 % encapsulation efficiency. Additionally, the antioxidant properties of QC contributed to enhancing the performance of the DDS. In vitro drug release studies of the final product, MIL-100@QC@L1, were successfully conducted. The cytotoxic influences of the formulation on MDA-MB-231 cells were assessed using the WST-1 assay. After treatment with 10 μg/mL of MIL-100@QC@L1 for 24 h, the cell viability decreased significantly to 47.8 %, showing superior results compared to treatments with L0 and L1 alone.

Açıklama

Anahtar Kelimeler

Drug Delivery System, Lenalidomide-Like Novel Drug Derivative, MIL-100 (Fe), Quercetin, Triple Negative Breast Cancer

Kaynak

Journal of Drug Delivery Science and Technology

WoS Q Değeri

Q1

Scopus Q Değeri

Q1

Cilt

108

Sayı

Künye

Özsoy, M., Pirinçci Tok, Y., Güney Eskiler, G., Tok, F., Karakuş, S., Özsoy, Y., & Özaçar, M. (2025). The lenalidomide derivative loaded and quercetin modified MIL-100 based novel drug delivery system for breast cancer treatment. Journal of Drug Delivery Science and Technology, 108, pp. 1-11. https://doi.org/10.1016/j.jddst.2025.106923